NASDAQ: RDHL - RedHill Biopharma Ltd.

Rentabilität für sechs Monate: -68.88%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan RedHill Biopharma Ltd.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen RedHill Biopharma Ltd.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

weitere details
Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2013-01-07
ISIN US7574681034
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.redhillbio.com
Цена ао 2.75
Preisänderung pro Tag: -1.09% (2.75)
Preisänderung pro Woche: -9.03% (2.99)
Preisänderung pro Monat: -29.35% (3.85)
Preisänderung über 3 Monate: -60.64% (6.91)
Preisänderung über sechs Monate: -68.88% (8.7406)
Preisänderung pro Jahr: +413.3% (0.5299)
Preisänderung über 3 Jahre: -7.17% (2.93)
Preisänderung über 5 Jahre: -36.6% (4.29)
Preisänderung seit Jahresbeginn: -59.22% (6.67)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 36.55 1
P/BV 115.06 1
P/E 9.95 9
EV/EBITDA -7.93 0
Gesamt: 5.38

Effizienz

Name Bedeutung Grad
ROA, % 103.77 10
ROE, % 1155.91 10
Gesamt: 5

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0399 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 3.38 1
Rentabilität Ebitda, % -164.64 0
Rentabilität EPS, % -106.74 0
Gesamt: 0.2
Weitere Details

Institutionen Volumen Aktie, %
Gagnon Securities, LLC 89589 10.16
JANE STREET GROUP, LLC 86812 9.85
Rhumbline Advisers 34847 3.95
We Are One Seven, LLC 15750 1.79
Squarepoint Ops LLC 10947 1.24
Group One Trading, L.P. 615 0.07
Morgan Stanley 576 0.07
Aspire Private Capital, LLC 405 0.05
Royal Bank of Canada 142 0.02
Steward Partners Investment Advisory, LLC 125 0.01



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Dror Ben-Asher Co-Founder, Chairman & CEO 594.61k 1966 (59 Jahre)
Mr. Gilead Raday MPhil, MSc Chief Operating Officer 365.56k 1975 (50 Jahre)
Mr. Adi Frish Chief Corporate & Business Development Officer 339.3k 1970 (55 Jahre)
Mr. Rick D. Scruggs Chief Commercial Officer, President of RedHill Biopharma Inc. & Director 469.8k 1960 (65 Jahre)
Mr. Razi Ingber Chief Financial Officer 339.82k 1984 (41 Jahr)
Ms. Alexandra Okmian Senior Business Development & Investor Relations Manager N/A
Dr. Reza Fathi Ph.D. Senior Vice President of Research & Development 299.29k 1955 (70 Jahre)
Ms. Patricia Anderson B.Sc. RAC Senior Vice President of Regulatory Affairs N/A
Mr. Guy Goldberg J.D. Chief Business Officer 338.13k 1976 (49 Jahre)

Adresse: Israel, Tel Aviv, 21 Ha’arba’a Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.redhillbio.com